ImmunityBio (NASDAQ:IBRX) stock rose 10% Friday morning after the company said it has received Regenerative Medicine Advanced Therapy designation for Anktiva and CAR-NK, or PD-L1 t-haNK.
The designation is for the reversal of lymphopenia in patients receiving standard-of-care chemotherapy/radiotherapy and in the treatment of multiply relapsed locally advanced or metastatic pancreatic cancer, according to a statement.
ImmunityBio (NASDAQ:IBRX) added that it plans to file an Expanded Access Policy for Anktiva and PD-L1 t-haNK in combination with standard of care chemotherapy/radiotherapy within fifteen days and submit the protocol to the FDA.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.